Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
Delayed Quote. Delayed Swiss Exchange - 08/16 11:30:15 am
87.52 CHF   +1.23%
08/16EUROPE MARKETS: After Wild Week, Europe Stocks Trade Higher
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
88.96(c) 88.63(c) 87.6(c) 86.46(c) 87.52(c) Last
4 716 029 4 910 723 5 023 509 5 474 878 4 364 158 Volume
+0.82% -0.37% -1.16% -1.30% +1.23% Change
More quotes
Financials (USD)
Sales 2019 46 921 M
EBIT 2019 13 831 M
Net income 2019 9 621 M
Debt 2019 17 640 M
Yield 2019 3,32%
Sales 2020 49 204 M
EBIT 2020 14 928 M
Net income 2020 9 561 M
Debt 2020 11 181 M
Yield 2020 3,45%
P/E ratio 2019 20,9x
P/E ratio 2020 21,4x
EV / Sales2019 4,74x
EV / Sales2020 4,39x
Capitalization 205 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (67.2%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
09/05Presentation
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
08/16EUROPE MARKETS: After Wild Week, Europe Stocks Trade Higher
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/14NOVARTIS : Correction to Story on Executive Changes at Novartis
DJ
08/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/14NOVARTIS : Replaces Two Researchers Amid Data Scandal
DJ
08/14NOVARTIS : names Bulto as new head of U.S. drugs business
RE
08/12NOVARTIS : Sandoz will appeal District Court of New Jersey ruling in biosimilar ..
AQ
08/12AMGEN : Wins Patent Case on Enbrel
AQ
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 2018
Technically solid
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
08/16ABBVIE : Gets FDA OK for Rheumatoid Arthritis Drug Rinvoq
DJ
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/16NOVO NORDISK : contests Danish lawsuit claiming $1.75 billion
RE
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 94,18  $
Last Close Price 89,36  $
Spread / Highest target 20,2%
Spread / Average Target 5,40%
Spread / Lowest Target -9,84%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS17.81%202 958
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
PFIZER-21.01%190 711